salmeterol信息详情
n.沙美特罗（β2促效剂、扩张支气管）
Salmeterol increase risk of death in asthma patients?───美特罗会提高哮喘病人的死亡可能性？
Objective To evaluate the clinical effect of inhaling salmeterol-fluticasone on patients with COPD.───目的探讨吸入沙美特罗-替卡松粉治疗慢性阻塞性肺疾病（COPD）的疗效。
Results: Salmeterol and fluticasone propionate powder marked improvement in asthma symptoms.───结果：沙美特罗替卡松粉剂明显改善哮喘病状。
abstract: Objective: To observe the efficacy of salmeterol and fluticasone propionate treating children with midrange asthma.───目的：观察用沙美特罗联合丙酸氟替卡松治疗儿童中度哮喘疗效。
Objective: To observe salmeterol and fluticasone propionate inhalation powder on the treatment of bronchial asthma, and security.───目的：观察沙美特罗替卡松粉剂吸入后对支气管哮喘的治疗效果、安全性。
Aim To develop a new synthetic route to salmeterol.───目的研究开发平喘药沙美特罗的新合成路线。
Treatment Effect of Salmeterol Combined with Singulair on Hormone- dependent Bronchial Asthma───舒利迭联合顺尔宁治疗激素依赖型支气管哮喘临床分析
Determination of Residual Organic Solvents in Salmeterol Xinafoate by Capillary Gas Chromatography───羟萘甲酸沙美特罗中有机溶剂残留量的气相色谱法测定
Our study allowed us to estimate dose equivalence from the dose response findings with salbutamol and salmeterol.
Compared with regular salbutamol, regular salmeterol was not associated with a significant increase in fatal or nonfatal serious adverse events in patients not taking inhaled corticosteroids.
Salmeterol could therefore reduce the efficacy of salbutamol when the two are given in combination.
Conclusion Salmeterol and fluticasone propionate inhalant can improve pulmonary function in COPD patients.